维普期刊资源整合服务平台（V6.5）

70篇 您的检索式：作者名="ZIEPERT M"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Conventional chemoimmunotherapy(R-CHOEP-14)or high-dose therapy(R-Mega-CHOEP)for young,high-risk patients with aggressive B-cell lymphoma:Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group(DSHNHL)显示文摘	Schmitz N Nickelsen M Ziepert M	2011	J Clin Oncol2011，29，15：	1
2	Prognostic factors of hematotoxicity of chemotherapy in aggressive non - Hodgkin's lymphoma显示文摘	ZIEPERT M SCHMITS R TRUMPER L	2008	Ann Oncol2008，19，4：	1
3	High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma 显示文摘	Glass B Ziepert M Reiser M	2010	Ann Oncol2010，21，11：	1
4	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+B-cell lymphomas:a randomised controlled trial(RICOVER-60)显示文摘	Pfreundschuh M Schubert J Ziepert M	2008	Lancet Oncol2008，9，2：	1
5	Conventional chemothera- py (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-ceU lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)显示文摘	Schmitz N Nickelsen M Ziepert M	2012	Lancet Oncol2012，13，12：	1
6	Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group显示文摘	Schmitz N Trümper L Ziepert M	2010	Blood2010，116，18：	1
7	Immunoblastic morphology but not the immounohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL显示文摘	Ott G Ziepert M Klapper W	2010	Blood2010，116，23：	1
8	Six versus eight cycles of bi-weekly CHOP-14 with or without ritux- imab in elderly patients with aggressive CD20 +B-cell lymphomas: a randomised controlled trial (RICOVER-60) 显示文摘	Pfreundschuh M Schubert J Ziepert M	2008	Lancet 0ncol2008，9，2：	1
9	Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma-analyses of cases from two prospective randomized clinical trials显示文摘	Bernd HW Ziepert M Thorns C	2009	Haematologica2009，94，11：	1
10	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60)显示文摘	PFREUNDSCHUH M SCHUBERT J ZIEPERT M	2008	Lancet Oncol2008，9，1：	1
11	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patientswith aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60) 显示文摘	Pfreundschuh M Schubert J Ziepert M	2008	Lancet Oncol2008，9，2：	1
12	Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group显示文摘	Schmitz N Trtimper L Ziepert M	2010	Blood2010，116，18：	1
13	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma显示文摘	Horn H Ziepert M Becher C	2013	Blood2013，121，12：	1
14	Treatment and prognosis of mature T-ceil and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group 显示文摘	Schmitz N Trumper L Ziepert M	2010	Blood2010，116，18：	1
15	Standard International prognostic index remains a valid predictor of outcome for pa- tients with aggressive CD20+ B-cell lymphoma in the rituximab era显示文摘	Ziepert M Hasendever D Kuhnt E	2010	Clin Oncol2010，28，14：	1
16	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas:a randomised controlled trial (RICOVER-60)显示文摘	Pfreundschuh M Schubert J Ziepert M		0，，02：	1
17	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma 显示文摘	Horn H Ziepert M Becher C	2013	Blood2013，121，12：	1
18	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60)显示文摘	PFREUNDSCHUH M SCHUBERT J ZIEPERT M	2008	Lancet Oncol2008，9，1：	1
19	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas:a randomised controlled trial (RICOVER-60) 显示文摘	Pfreundschuh M Schubert J Ziepert M	2008	Lancet Onco12008，9，1：	1
20	High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma显示文摘	Glass B Ziepert M Reiser M		0，，11：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示